398 related articles for article (PubMed ID: 23710592)
1. Posaconazole prophylaxis--impact on incidence of invasive fungal disease and antifungal treatment in haematological patients.
Peterson L; Ostermann J; Rieger H; Ostermann H; Rieger CT
Mycoses; 2013 Nov; 56(6):651-8. PubMed ID: 23710592
[TBL] [Abstract][Full Text] [Related]
2. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study.
Lerolle N; Raffoux E; Socie G; Touratier S; Sauvageon H; Porcher R; Bretagne S; Bergeron A; Azoulay E; Molina JM; Lafaurie M
Clin Microbiol Infect; 2014 Nov; 20(11):O952-9. PubMed ID: 24861577
[TBL] [Abstract][Full Text] [Related]
3. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
Dahlén T; Kalin M; Cederlund K; Nordlander A; Björkholm M; Ljungman P; Blennow O
Eur J Haematol; 2016 Feb; 96(2):175-80. PubMed ID: 25880378
[TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.
Vehreschild JJ; Rüping MJ; Wisplinghoff H; Farowski F; Steinbach A; Sims R; Stollorz A; Kreuzer KA; Hallek M; Bangard C; Cornely OA
J Antimicrob Chemother; 2010 Jul; 65(7):1466-71. PubMed ID: 20410061
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
[TBL] [Abstract][Full Text] [Related]
6. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study.
Auberger J; Lass-Flörl C; Aigner M; Clausen J; Gastl G; Nachbaur D
J Antimicrob Chemother; 2012 Sep; 67(9):2268-73. PubMed ID: 22653819
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.
Vehreschild MJ; von Bergwelt-Baildon M; Tran L; Shimabukuro-Vornhagen A; Wisplinghoff H; Bangard C; Cornely OA; Vehreschild JJ
Eur J Haematol; 2014 Nov; 93(5):400-6. PubMed ID: 24798021
[TBL] [Abstract][Full Text] [Related]
8. European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies.
Hoenigl M; Strenger V; Buzina W; Valentin T; Koidl C; Wölfler A; Seeber K; Valentin A; Strohmeier AT; Zollner-Schwetz I; Raggam RB; Urban C; Lass-Flörl C; Linkesch W; Krause R
J Antimicrob Chemother; 2012 Aug; 67(8):2029-33. PubMed ID: 22566591
[TBL] [Abstract][Full Text] [Related]
9. Preventing invasive fungal disease in patients with haematological malignancies and the recipients of haematopoietic stem cell transplantation: practical aspects.
Akan H; Antia VP; Kouba M; Sinkó J; Tănase AD; Vrhovac R; Herbrecht R
J Antimicrob Chemother; 2013 Nov; 68 Suppl 3():iii5-16. PubMed ID: 24155144
[TBL] [Abstract][Full Text] [Related]
10. Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients.
Bochennek K; Tramsen L; Schedler N; Becker M; Klingebiel T; Groll AH; Lehrnbecher T
Clin Microbiol Infect; 2011 Dec; 17(12):1868-74. PubMed ID: 21895857
[TBL] [Abstract][Full Text] [Related]
11. Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.
Montesinos P; Rodríguez-Veiga R; Boluda B; Martínez-Cuadrón D; Cano I; Lancharro A; Sanz J; Arilla MJ; López-Chuliá F; Navarro I; Lorenzo I; Salavert M; Pemán J; Calvillo P; Martínez J; Carpio N; Jarque I; Sanz GF; Sanz MA
Bone Marrow Transplant; 2015 Nov; 50(11):1465-72. PubMed ID: 26281032
[TBL] [Abstract][Full Text] [Related]
12. The role of primary antifungal prophylaxis in patients with haematological malignancies.
Pagano L; Caira M
Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():19-26. PubMed ID: 24372659
[TBL] [Abstract][Full Text] [Related]
13. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?
Rogers TR; Slavin MA; Donnelly JP
Br J Haematol; 2011 Jun; 153(6):681-97. PubMed ID: 21504422
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
[TBL] [Abstract][Full Text] [Related]
15. Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis.
Heimann SM; Cornely OA; Vehreschild MJ; Glossmann J; Kochanek M; Kreuzer KA; Hallek M; Vehreschild JJ
Mycoses; 2014 Feb; 57(2):90-7. PubMed ID: 23790060
[TBL] [Abstract][Full Text] [Related]
16. Primary antifungal prophylaxis: decrease of invasive fungal disease incidence and reduction of risk factors in haematological patients in a 5-year retrospective study.
Li Y; Liu M; Zhai B; Zhao X; Wang L; Li H; Wang S; Zhu H; Wang Q; Gao C; Huang W; Yu L
Intern Med J; 2018 Jun; 48(6):713-720. PubMed ID: 29230923
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia.
Schrenk KG; Schnetzke U; Stegemann K; von Lilienfeld-Toal M; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1661-8. PubMed ID: 25800622
[TBL] [Abstract][Full Text] [Related]
18. Triazole antifungals used for prophylaxis and treatment of invasive fungal disease in adult haematology patients: Trough serum concentrations in relation to outcome.
Ceesay MM; Couchman L; Smith M; Wade J; Flanagan RJ; Pagliuca A
Med Mycol; 2016 Oct; 54(7):691-8. PubMed ID: 27161786
[TBL] [Abstract][Full Text] [Related]
19. Posaconazole prophylaxis in neutropenic patients with hematological malignancies: limits in clinical practice.
Bourdelin M; Grenouillet F; Daguindau E; Muret P; Desbrosses Y; Dubut J; Deconinck E; Limat S; Larosa F
Med Mycol; 2014 Oct; 52(7):728-35. PubMed ID: 25012993
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry.
Vehreschild JJ; Sieniawski M; Reuter S; Arenz D; Reichert D; Maertens J; Böhme A; Silling G; Martino R; Maschmeyer G; Rüping MJ; Ullmann AJ; Cornely OA
Int J Antimicrob Agents; 2009 Nov; 34(5):446-50. PubMed ID: 19700265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
